•  
  •  
  •  
  •  

2026-07-20 03:29:30

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Can Fin Homes Limited Delivers Strong Opening to FY27: Net Profit Rises 20% to ₹268 Crore Driven by Robust Disbursements
  • Punjab & Sind Bank Registers 23.05% Net Profit Surge in Q1 FY27 Powered by Robust Credit Growth and Improving Asset Quality
  • Bhansali Engineering Polymers Limited Marks Strong Start to FY27: Q1 Consolidated Net Profit Surges 42.9% to ₹65.60 Crore
  • Sangam India Ltd Reports Surge in Q1 FY27 Net Profit to ₹4,102 Lakhs
  • Rossari Biotech Limited Posts Steady Q1 FY27 Growth: Net Profit Rises to ₹350.95 Million

Keywords Selected:  TentativeApproval

Stock Report

  • Alembic Pharmaceuticals Limited's Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets, 100 mg and 150 mg
  • NATCO receives Tentative Approval for Olaparib Tablets from the U.S. FDA
  • Lupin receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
  • Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Binimetinib Tablets, 45 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg
  • Orbicular's Partner secures tentative U.S. ANDA approval for a generic version of Semaglutide Injection, supported by OneSource as CDMO partner
  • Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection
  • Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets
  • Zydus receives tentative approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg
  • NATCO receives Tentative Approval for Erdafitinib Tablets from USFDA
  • Lupin receives tentative approval from U.S. FDA for Siponimod Tablets
  • Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg
  • Zydus receives tentative approval from USFDA for Olaparib Tablets, 100 mg and 150 mg
  • Zydus receives tentative approval from USFDA for Budesonide delayedrelease capsules, 4 mg
  • Biocon Pharma Ltd in partnership with Carnegie Pharmaceuticals LLC receives USFDA tentative approval for Rifaximin Tablets
  • Zydus receives tentative approval from USFDA for Ibrutinib tablets 140 mg, 280 mg, and 420 mg
  • Lupin receives tentative approval from U.S. FDA for Oxcarbazepine ER Tablets
  • Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg
  • Lupin receives tentative approval from U.S. FDA for Amifampridine Tablets
  • Alembic Pharmaceuticals Ltd announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
  • Zydus receives tentative approval from USFDA for Enzalutamide Tablets, 40 mg and 80 mg
  • Gland Pharma receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution
  • Alembic Pharmaceuticals announces USFDA Tentative Approval for Selexipag for Injection, 1,800 mcg/vial
  • Zydus receives tentative approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg

Latest Post

  • Can Fin Homes Limited Delivers Strong Opening to FY27: Net Profit Rises 20% to ₹268 Crore Driven by Robust Disbursements
  • Punjab & Sind Bank Registers 23.05% Net Profit Surge in Q1 FY27 Powered by Robust Credit Growth and Improving Asset Quality
  • Bhansali Engineering Polymers Limited Marks Strong Start to FY27: Q1 Consolidated Net Profit Surges 42.9% to ₹65.60 Crore
  • Sangam India Ltd Reports Surge in Q1 FY27 Net Profit to ₹4,102 Lakhs
  • Rossari Biotech Limited Posts Steady Q1 FY27 Growth: Net Profit Rises to ₹350.95 Million


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025